In this multi-center study, the feasibility, safety, and efficacy of radiofrequency (RF) energy delivery to the gastroesophageal junction (GEJ) for the treatment of gastroesophageal reflux disease (GERD) were investigated. Methods: Forty-seven patients with classic symptoms of GERD (heartburn and/or regurgitation), a daily anti-secretory medication requirement, and at least partial symptom response to drugs were enrolled. All patients had pathologic esophageal acid exposure by 24-hour pH study, a 2 cm or smaller hiatal hernia, grade 2 or less esophagitis, and no significant dysmotility or dysphagia. RF energy was delivered with a catheter and thermocouple-controlled generator to create submucosal thermal lesions in the muscle of the GEJ. GERD symptoms and quality of life were assessed at 0, 1, 4, and 6 months with the short-form health survey (SF-36). Anti-secretory medications were withdrawn 7 days before each assessment of symptoms and pH/motility study. Medication use, endoscopic findings, esophageal acid exposure, and motility were assessed at 0 and 6 months. 
Low-resting lower esophageal sphincter pressure (LESP), frequent transient LES relaxations (tLESRs), or hiatal hernia may result in pathologic exposure of the esophagus to gastric contents (acid, pepsin, pancreatic enzymes, and bile). [3] [4] [5] Reflux may cause symptoms of heartburn, regurgitation, or dysphagia, or may cause the development of esophagitis, Barrett's metaplasia, and adenocarcinoma. [3] [4] [5] [6] Histamine-2 receptor antagonists (H2RA) relieve heartburn in 60% of patients and heal esophagitis in 50%, [5] [6] [7] whereas proton pump inhibitors (PPI) relieve heartburn in 80% of patients and heal esophagitis in 90%. [5] [6] [7] Esophagitis recurs in 80% of patients after cessation of drug therapy. 7 Laparoscopic fundoplication improves symptoms in 76% to 98% of patients, normalizes esophageal acid exposure time in 90%, 8 and may be elected by patients with disease refractory to drug treatment, intolerance to medication, or those who simply prefer surgery to drug therapy. Despite its impressive effiGastroesophageal reflux affects 19.8% of adults in the United States on a weekly basis 1 and has an adverse impact on quality-of-life similar to that of angina pectoris, heart failure, and duodenal ulcer. 2 cacy, the possible risks of surgery and general anesthesia and the potential for postoperative dysphagia and bloating remain obstacles for many patients.
An endoscopic approach to the treatment of gastroesophageal reflux disease (GERD) would be desirable, if such an approach was well tolerated, safe, and effective. In this regard, temperature-controlled delivery of radiofrequency (RF) energy is used to ablate specific tissue targets, such as nerve pathways (i.e., cardiac arrhythmias), 9 and to tighten tissue, such as lax joint capsules. l0 Transient LES relaxations are considered the predominant cause of GERD and result from afferent vagal pathway signals emanating from the gastric cardia to the hindbrain. 3 RF ablation of these intramural pathways in a canine model reduced tLESRs by 54% 11 and in a study in humans by 44%. 12 Furthermore, in a porcine model, RF energy tissue tightening augmented LESP and the resistance to reflux during gastric distension (gastric yield pressure [GYP]) 13 similar to fundoplication. 14 These results prompted this multi-center clinical study to determine the safety and efficacy of RF energy delivery with respect to GERD symptoms, quality of life, medication use, and esophageal acid exposure.
PATIENTS AND METHODS

Study population
The study included 32 men and 15 women with GERD (mean age 48.6 years, range 22-74, mean body mass 87.3 kg, range 52-176) ( Table 1 ). The number of years with GERD symptoms was 9.6 ± 8.5 years (mean ± SD). Patients were either self-referred or recruited from the principal investigators' clinical practices. Patients were included if they had chronic heartburn and/or regurgitation, a daily anti-secretory medication requirement, and at least partial symptom response to drugs. All patients had a peak esophageal peristaltic amplitude of greater than 30 mm Hg, LESP greater than 5 mm Hg, complete LES relaxation in response to swallow, and either an esophageal acid exposure time of greater than 4.0% or a DeMeester score of greater than 14.7. 15 All had normal esophageal mucosa or Hetzel grade 1 or 2 esophagitis 16 and none had a hiatal hernia of greater than 2 cm. Five patients (10.6%) had hiatal hernias (2 cm or less). Many patients had prior endoscopic evaluation or barium swallow, allowing pre-enrollment determination of candidacy with respect to hiatal hernia, Barrett's esophagus, or severe esophagitis. Additionally, all patients underwent endoscopy at the time of RF treatment as part of the procedure and patients were excluded if endoscopy disclosed a hiatal hernia more than 2 cm long, esophagitis of greater than Grade 2, or findings suggestive of Barrett's esophagus. Also excluded were patients who were pregnant or poor candidates for surgery or who had severe dysphagia, previous esophageal or gastric surgery, Barrett's esophagus, collagen vascular disease, or untreated significant medical conditions.
Study design
The Institutional Review Board (IRB) of each participating institution approved the study protocol. Subjects who met the inclusion criteria, based on the initially available patient information, underwent the informed consent process and signed the consent form. Each subject completed the validated GERD-Health Related Quality of Life questionnaire (GERD-HRQL) 17 and the Medical Outcomes Study SF-36 18 while following their current antisecretory medication regimen. The questionnaires were administered a second time after discontinuing the drug regimen (3-5 days for H2RAs and 7 days for PPIs) to assess baseline symptoms without treatment. If pH and motility data obtained within the previous 6 months were not available, these were obtained with the patient taking no medication as described above.
Esophageal manometry with the station pull-through technique was performed before (mean ± SD, 1.5 ± 2.4 months) and after treatment (5.6 ± 1.4 months). Patients discontinued the use of antisecretory medication for the performance of these procedures. Studies were interpreted blindly at each center by individuals who were not members of the study team. LES pressure (mid-expiratory), length, relaxation, and peristaltic amplitude were measured. In all but one center, the constant perfusion system and Medtronic software (Medtronic Functional Diagnostics, Shoreview, Minn.) were used for the motility studies. At one center, the solid state system was used.
Patients underwent 24-hour ambulatory esophageal pH monitoring before (1.3 ± 2.2 months) and after treatment (6.1 ± 1.1 months) after discontinuing H 2 RA therapy for 3 to 5 days and PPI therapy for 7 days. In all patients, an ambulatory pH sensor (Digitrapper, Medtronic, Inc., Minneapolis, Minn.) was passed transnasally and positioned 5 cm proximal to the manometricallydefined upper border of the LES. Twenty-one patients had dual sensor pH monitoring 5 cm and 20 cm proximal to the LES. Four patients were unable to discontinue PPI therapy for pretreatment 24-hour pH testing due to intolerable heartburn. The Medtronic software was used to interpret the 24-hour pH studies. If patients met all inclusion criteria and no exclusion criterion, they were enrolled in the study and the procedure performed. Anti-secretory medication was continued for 21 days after the procedure to facilitate healing of any mucosal injury that occurred during treatment, then discontinued. Follow-up questionnaires were completed with patients taking no medication at 1, 4, and 6 months after treatment. The GERD-HRQL assesses GERD symptoms (scale of 0-50) and patient satisfaction (scale of 0-5). 17 The SF-36 assesses quality of life and is summarized as a physical (PCS) and mental (MCS) component summary (normal, 50 each). 18 At each interval, patients were queried about dysphagia, regurgitation, and flatulence/bloating (present or absent) with a separate questionnaire. Medication use was measured at baseline and at each follow-up interval with a patient case report form that queried the type, dose, and frequency of use of all anti-secretory or antacid preparations. If the patient had used any such medication in the preceding month during follow-up, he or she was considered a user of medication at that time interval. All questionnaire responses were processed in a blinded manner to minimize bias. If GERD symptoms returned after discontinuing anti-secretory medication, step-wise rescue therapy was implemented, initiated by a phone call to the study coordinator, followed by instructions for use of a liquid antacid preparation. If symptoms persisted, ranitidine 300 mg twice daily was prescribed. Finally, the original drug regimen (in the case of prior PPI use) was reinstituted if ranitidine was inadequate. The use of the rescue medication was discontinued for completion of the followup questionnaire and pH testing. Endoscopy was performed at 0 and 6 months to assess for the presence of esophagitis and evidence of previous RF treatment. 
Radiofrequency energy delivery technique
Radiofrequency energy delivery was performed on an outpatient basis in the endoscopy unit. All patients received a combination of intravenous fentanyl or meperidine and midazolam, while 10 received cefazolin (1 gm intravenously) at the request of the IRB. Endoscopy was performed, the distance from the incisors to the squamocolumnar junction (z-line) measured, and the endoscope removed. A flexible RF energy catheter comprised of a bougie tip, a balloonbasket assembly, and 4 electrode delivery sheaths positioned radially around the balloon was passed transorally and positioned 2 cm distal to the level of the z-line (Fig. lA) . The balloon was inflated and 4 nickel-titanium needle electrodes (22 gauge, 5.5 mm length) were deployed into the muscle of the gastroesophageal junction (GEJ) (Fig. lB) . The RF system has an intrinsic mechanism for constant monitoring of tissue impedance. When the needles are properly deployed within the muscle of the GEJ, there is a distinctive reduction in impedance that is different than that which occurs with simple mucosal contact, typically from greater than 500 ohms to 100 to 300 ohms, that confirms muscle contact. A 4-channel RF generator delivered RF energy (465 kHz, 2-5 watts) to each needle electrode. Temperature was monitored at the tip of each needle, allowing modulation of power output to achieve a target tissue temperature of 85°C for 2 minutes. Mucosal temperature was similarly monitored and maintained below 30°C by delivering chilled plain water (30 mL/min) through the catheter tip, while suctioning via a separate channel to avoid fluid accumulation. Additional lesion sets were created in the region from 2 cm proximal to 2 cm distal to the zline by rotating the catheter 45 degrees and changing its linear position (Fig. lC and D) . A total of 12 to 15 lesion sets were created in most patients, a number determined in a previous animal model investigation and by the patient's individual anatomy. All patients underwent endoscopy immediately after delivery of RF energy to assess the appearance of the mucosa.
Statistical analysis
Data were analyzed with SAS software (SAS Institute, Cary, N.C.). Continuous outcomes from questionnaires, pH, and motility studies were evaluated by computing the difference between the 0-and 6-month values and applying the Wilcoxon signed rank test. Categorical outcomes were evaluated using McNemar's test for binary data (medication use, regurgitation, dysphagia, bloating) and Bowker's test of symmetry (esophagitis). 
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Intent-to-treat analysis was performed by using the last value carried forward method. Thus, patients with missing pH or manometry data at 6 months were considered not improved for the purposes of the intent-to-treat analysis. Repeated measures analysis was performed on quality-of-life measurements at 1, 4, and 6 months with Generalized Estimating Equations (GEE). The correlation structure in the GEE analysis was "unstructured" (each element in the correlation matrix allowed to vary). Subgroup analyses were performed to determine the effect of baseline characteristics on treatment outcome by using GERD-HRQL score, medication use, and esophageal acid exposure time. Baseline characteristics were dichotomized as follows: age (<50, ≥50), gender, years with GERD (<6, ≥6), LESP (<10 mm Hg, ≥10 mm Hg), esophageal amplitude (<40 mm Hg, ≥40 mm Hg), acid exposure time (≤5.5%, >5.5%), and esophagitis (yes, no), and analyzed with the Wilcoxon rank sum test.
RESULTS Feasibility
Delivery of RF energy was completed in all patients. Patients received midazolam (mean 6.7 mg, range 2.0-13.5) and either fentanyl (mean 134 µg, range 75-275) or meperidine (mean 114 mg, range 12.5-300). Multiple lesion sets were created (mean 13.8 ± 2.5), with a mean total procedure time of 69 ± 17 minutes and RF energy delivery lasting 52 ± 10 minutes.
Safety and patient tolerance
Discomfort due to catheter passage was none (75%) or mild (25%). Discomfort with RF energy delivery was none (26%), mild (57%), moderate (13%), or severe (4%). The discomfort was associated with the inflation of the balloon and delivery of RF energy. The discomfort dissipated immediately upon termination of RF energy delivery. When more than mild discomfort occurred, additional medication was given. Two patients had superficial mucosal ulceration immediately after treatment, whereas at 6 months there were no ulcers or stricture in any patient. There were 3 complications: fever, odynophagia, and mucosal injury. One patient developed a fever (37.7°C) without dysphagia, chest pain, or abdominal pain 48 hours after the procedure. A chest radiograph and white blood cell count were normal. The fever resolved in 24 hours without intervention. Another patient experienced odynophagia 12 days after the procedure. Barium esophagram, chest CT, and esophagoscopy were normal. Symptoms resolved over 5 days. A third patient had a superficial linear mucosal injury in the distal esophagus before delivery of RF energy, which occurred during catheter positioning, resulting in postponement of the procedure. Endoscopy was repeated 3 weeks later, at which time the esophageal mucosa was healed and RF energy delivery was performed successfully.
At 6 months, no new cases of dysphagia were reported and there was no effect on peristaltic amplitude, LES pressure (Fig. 2) , LES length, or LES relaxation (Table 2) . Three patients reported new flatulence or bloating (7%).
Efficacy
Median heartburn scores improved from 4 at baseline off-medication to 1 (p ≤ 0.0001, Fig. 3A , Table 2 ). This represented improvement for 36 patients, no change for 6, and worsening for 1. Median GERD-HRQL scores improved from 26 to 7 (p ≤ 0.0001, Fig.  3B , Table 2 . This represented improvement for 40 patients, no change for 1, and worsening for 2. Median patient satisfaction scores improved from 1 to 4 (p ≤ 0.0001, Fig. 3C , Table 2 ). This represented improvement in this score for 40 patients, no change for 2, and worsening for 1. Improvements for all parameters persisted when intent-to-treat analysis was applied (p ≤ 0.0001). Four patients did not complete questionnaires at 6 months. These patients were contacted by telephone and it was confirmed that they had not experienced any adverse event or worsening of symptoms after the procedure. Two of these patients reported that they were not taking antisecretory drugs and 2 had continued to take medication. Repeated measures analysis for heartburn, GERD-HRQL, and satisfaction showed that scores were constant and improved across the 1, 4, and 6 month follow-up visits (p ≤ 0.0001). As a comparison with standard medical therapy, scores at 6 months were compared with those at baseline while taking medication. Statistically significant improvement was noted in GERD-HRQL (p = 0.001) and satisfaction (p < 0.0001) (Fig. 3B and C) . Heartburn scores at 6 months were statistically equivalent to scores at baseline with medical therapy, although the mean was improved at 6 months. Regarding quality-of-life, median PCS improved from 41.1 to 51.9 (p = 0.0001, Fig. 3D , Table 2 ) and median MCS improved from 46.2 to 55.5 (p = 0.005, Fig. 3E , Table 2 ). Repeated measures showed that MCS improved gradually and reached significance at 6 months, whereas PCS scores significantly improved at 1, 4, and 6 months (p < 0.0001). Dysphagia, flatulence/bloating, and regurgitation were present in 30%, 81%, and 83% of patients, respectively, at baseline and 2%, 16%, and 34% (p = 0.001) at 6 months. The median drug requirement at baseline was the equivalent of 40 mg of omeprazole per day A B D C E whereas at 6 months 31 patients (70%) were not taking any anti-secretory drugs and 36 (87%) were able to discontinue the use of PPI drugs (p ≤ 0.001) (Fig. 4) . Before treatment, 13 (28%) patients supplemented their anti-secretory therapy with antacids, whereas at 6 months no patient used supplemental antacid and 7% of patients used antacids as their only treatment for GERD symptoms.
Esophagitis was present in 25 patients before treatment (15 Grade 1 and 10 Grade 2) whereas 8 had esophagitis at 6 months (4 Grade 1 and 4 Grade 2). Esophagitis resolved in 17 patients, developed in 2 patients, and worsened in 1 patient (p = 0.005).
Median distal esophageal acid exposure time improved from 11.7% to 4.8% (p ≤ 0.0001) (Fig. 5 ) and median DeMeester score improved from 44.4 to 20.9 (p ≤ 0.0001) ( Table 2 ). Proximal esophageal acid exposure improved from 2.5% to 0.5% (p ≤ 0.0001). This improvement in acid exposure remained statistically significant when applying intent-to-treat analysis (p ≤ 0.0001).
Subgroup analysis
There were no significant differences in outcome for GERD symptoms, medication use, or esophageal acid exposure between subgroups based on the baseline characteristics of gender, years with GERD, baseline LESP, esophageal peristaltic amplitude, esophageal acid exposure time, or baseline presence of esophagitis. There was a statistically significant difference in the improvement in esophageal acid exposure seen in the group less than 50 years of age versus older patients, but this was not supported by similar differences in symptom or medication use in this subgroup analysis.
DISCUSSION
This multi-center study demonstrated that endoscopically-guided RF energy delivery to the GEJ safely reduces GERD symptoms, medication use, and esophageal acid exposure time, and improves quality-of-life and esophagitis in the majority of the study population, which represented a heterogeneous spectrum of clinical disease severity but with minimal active esophagitis or hiatal hernia. A group of patients were included with long-standing, classic GERD symptoms (heartburn and/or regurgitation) with at least a partial symptom response to antisecretory drug therapy. This diagnosis was confirmed with validated GERD symptom questionnaires, pH studies, and endoscopy in cases of erosive disease (Table 1 and 2, Figs. 2 and 3 ). That this patient group represents a broad spectrum of disease severity is further supported by the range of esophageal acid exposure times, daily medication requirements ranging from H2RAs to high-dose PPIs, and a wide range of GERD scores by GERD-HRQL scale.
Current therapy for GERD includes widely prescribed anti-secretory drugs, which are typically safe and well tolerated, 5 although life-long compliance with treatment may be difficult to achieve. Therapy with H2RA and PPI drugs improves or resolves GERD symptoms in 60% and 80% of patients, respectively, 5, 7 and heals esophagitis in 50% and 90%. 7 Normalization of esophageal acid exposure time is rarely achieved with drug therapy unless high doses are used. 19 Fundoplication entails specialized surgical skills, general anesthesia, a 2-to 5-hour operative time, [20] [21] [22] 2-to 3-day hospitalization, 8, 20 28 days to return to normal activity, 21 and is typically safe and well-tolerated. Perioperative complications occur in up to 20% of 
